Literature DB >> 21590294

Bone mineral density in ambulatory patients with multiple sclerosis.

Chrissa Sioka1, Stylianos Papakonstantinou, Andreas Fotopoulos, Yiannis Alamanos, Athanasia Georgiou, Sofia Tsouli, Sygliti-Henrietta Pelidou, Athanassios P Kyritsis, John Kalef-Ezra.   

Abstract

Multiple sclerosis (MS) may be associated with reduced bone mass and higher frequency of osteoporosis. Femoral and spinal bone mineral density (BMD) in 70 ambulatory MS patients (46 females and 24 males) was compared with 100 sex-, age-, and BMI-matched control individuals. BMD was reduced in male patients (lumbar spine 0.976 ± 0.114 g/cm(2) compared with 1.059 ± 0.147 g/cm(2) in controls, p = 0.024, total hip 0.946 ± 0.136 g/cm(2) compared to 1.036 ± 0.118 g/cm(2) in controls, p = 0.008, femoral neck 0.812 ± 0.136 g/cm(2) compared with 0.887 ± 0.135 g/cm(2) in controls p = 0.042), and only in the total hip in female patients (0.88 ± 0.127 g/cm(2) compared with 0.935 ± 0.112 g/cm(2) in controls, p = 0.018). Multivariate analysis demonstrated that the predominantly affected site was the hip. MS patients exhibit increased frequency of low bone mass compared with controls. Further studies should assess the etiologic factors and employ appropriate therapies.

Entities:  

Mesh:

Year:  2011        PMID: 21590294     DOI: 10.1007/s10072-011-0623-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  22 in total

1.  The effect of interferon beta 1B on bone mineral density in multiple sclerosis patients.

Authors:  Asuman Orhan Varoglu; Erhan Varoglu; Rezzan Bayraktar; Recep Aygul; Hizir Ulvi; Kadir Yildirim
Journal:  J Back Musculoskelet Rehabil       Date:  2010       Impact factor: 1.398

Review 2.  Multiple sclerosis and nutrition.

Authors:  Stefan Schwarz; Hans Leweling
Journal:  Mult Scler       Date:  2005-02       Impact factor: 6.312

3.  Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis.

Authors:  S R Schwid; A D Goodman; J E Puzas; M P McDermott; D H Mattson
Journal:  Arch Neurol       Date:  1996-08

4.  Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity.

Authors:  Salih Ozgocmen; Serpil Bulut; Nevin Ilhan; Arif Gulkesen; Ozge Ardicoglu; Yusuf Ozkan
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

5.  Bone status in multiple sclerosis: beyond corticosteroids.

Authors:  Sansin Tüzün; Ayşe Altintaş; Ilhan Karacan; Saliha Tangürek; Sebahattin Saip; Aksel Siva
Journal:  Mult Scler       Date:  2003-12       Impact factor: 6.312

6.  High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton.

Authors:  F Cosman; J Nieves; J Herbert; V Shen; R Lindsay
Journal:  J Bone Miner Res       Date:  1994-07       Impact factor: 6.741

Review 7.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

8.  Geographical variation in DXA bone mineral density in young European men and women. Results from the Network in Europe on Male Osteoporosis (NEMO) study.

Authors:  Stephen Kaptoge; Jose A da Silva; Kim Brixen; David M Reid; Heikki Kröger; Torben L Nielsen; Marianne Andersen; Claus Hagen; Roman Lorenc; Steven Boonen; Marie-Christine de Vernejoul; Jan J Stepan; Judith Adams; Jean-Marc Kaufman; Jonathan Reeve
Journal:  Bone       Date:  2008-04-16       Impact factor: 4.398

9.  Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis.

Authors:  Linn Hofsøy Steffensen; Svein Ivar Mellgren; Margitta T Kampman
Journal:  J Neurol       Date:  2009-10-01       Impact factor: 4.849

10.  Bone health in ambulatory individuals with multiple sclerosis: impact of physical activity, glucocorticoid use, and body composition.

Authors:  Mina C Mojtahedi; Erin M Snook; Robert W Motl; Ellen M Evans
Journal:  J Rehabil Res Dev       Date:  2008
View more
  5 in total

1.  The Combinational Role of Vitamin D and Other Conditions in Multiple Sclerosis Patients.

Authors:  Chrissa Sioka
Journal:  Ethiop J Health Sci       Date:  2022-01

Review 2.  Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.

Authors:  S Binks; R Dobson
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

3.  Lack of Association between Pulse Steroid Therapy and Bone Mineral Density in Patients with Multiple Sclerosis.

Authors:  Serap Zengin Karahan; Cavit Boz; Sevgi Kilic; Nuray Can Usta; Mehmet Ozmenoglu; Vildan Altunayoglu Cakmak; Sibel Gazioglu
Journal:  Mult Scler Int       Date:  2016-02-04

4.  Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study.

Authors:  Cecilia Smith Simonsen; Elisabeth Gulowsen Celius; Cathrine Brunborg; Chantal Tallaksen; Erik Fink Eriksen; Trygve Holmøy; Stine Marit Moen
Journal:  BMC Neurol       Date:  2016-12-05       Impact factor: 2.474

5.  Assessment of Biochemical and Densitometric Markers of Calcium-Phosphate Metabolism in the Groups of Patients with Multiple Sclerosis Selected due to the Serum Level of Vitamin D3.

Authors:  Natalia Niedziela; Krystyna Pierzchała; Jolanta Zalejska-Fiolka; Jacek T Niedziela; Ewa Romuk; Magdalena Torbus-Paluszczak; Monika Adamczyk-Sowa
Journal:  Biomed Res Int       Date:  2018-08-23       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.